磁共振波谱分析作为一种提高前列腺癌早期诊断和危险分层的新方法。
Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer.
机构信息
Department of Urology, Zhoupu Hospital, Shanghai University of Medicine & Health Sciences, Shanghai 201318, China.
Department of Urology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
出版信息
J Zhejiang Univ Sci B. 2017;18(11):921-933. doi: 10.1631/jzus.B1600441.
Prostate cancer (PCa) is the second most common male cancer worldwide and the fifth leading cause of death from cancer in men. Early detection and risk stratification is the most effective way to improve the survival of PCa patients. Current PCa biomarkers lack sufficient sensitivity and specificity to cancer. Metabolite biomarkers are evolving as a new diagnostic tool. This review is aimed to evaluate the potential of metabolite biomarkers for early detection, risk assessment, and monitoring of PCa. Of the 154 identified publications, 27 and 38 were original papers on urine and serum metabolomics, respectively. Nuclear magnetic resonance (NMR) is a promising method for measuring concentrations of metabolites in complex samples with good reproducibility, high sensitivity, and simple sample processing. Especially urine-based NMR metabolomics has the potential to be a cost-efficient method for the early detection of PCa, risk stratification, and monitoring treatment efficacy.
前列腺癌（PCa）是全球第二大常见男性癌症，也是男性癌症死亡的第五大主要原因。早期发现和风险分层是提高 PCa 患者生存率的最有效方法。目前的 PCa 生物标志物在癌症方面缺乏足够的灵敏度和特异性。代谢物生物标志物正在作为一种新的诊断工具发展。本综述旨在评估代谢物生物标志物在 PCa 的早期检测、风险评估和监测中的潜力。在确定的 154 篇文献中，有 27 篇和 38 篇分别为尿液和血清代谢组学的原始论文。核磁共振（NMR）是一种很有前途的方法，可用于测量具有良好重现性、高灵敏度和简单样品处理的复杂样品中代谢物的浓度。特别是基于尿液的 NMR 代谢组学具有成为一种经济有效的 PCa 早期检测、风险分层和监测治疗效果的方法的潜力。
Zotero 插件